Literature DB >> 10773092

Histone deacetylase-independent transcriptional repression by methyl-CpG-binding protein 2.

F Yu1, J Thiesen, W H Strätling.   

Abstract

Methyl-CpG-binding protein 2 (MeCP2) contains a transcriptional repression domain (TRD), which can act by recruitment of a large transcriptional co-repressor complex containing histone deacetylases HDAC1 and 2. We demonstrate here that transient transcription from the SV40 enhancer/promoter or the SV40 promoter is strongly repressed in a histone deacetylase-independent manner, since repression is not alleviated by Trichostatin A (TSA). In a mutational analysis, repression depends on a conserved 30 residue sequence containing two clusters of basic amino acids. Mutation of the first of these clusters inhibits in vitro interaction between TRD and mSin3A. Furthermore, a subdomain of the TRD containing the conserved 30-residue sequence and 16 flanking amino acids was sufficient to compromise VP16-activated transcription. In summary, our results indicate an alternative, histone deacetylase-independent pathway of transcriptional repression by MeCP2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773092      PMCID: PMC105362          DOI: 10.1093/nar/28.10.2201

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  25 in total

Review 1.  Origin and roles of nuclear matrix proteins. Specific functions of the MAR-binding protein MeCP2/ARBP.

Authors:  W H Strätling; F Yu
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1999       Impact factor: 1.807

2.  A 13-amino acid amphipathic alpha-helix is required for the functional interaction between the transcriptional repressor Mad1 and mSin3A.

Authors:  A L Eilers; A N Billin; J Liu; D E Ayer
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

3.  Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA.

Authors:  J D Lewis; R R Meehan; W J Henzel; I Maurer-Fogy; P Jeppesen; F Klein; A Bird
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

4.  Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor.

Authors:  R Eckner; M E Ewen; D Newsome; M Gerdes; J A DeCaprio; J B Lawrence; D M Livingston
Journal:  Genes Dev       Date:  1994-04-15       Impact factor: 11.361

5.  Nuclear matrix protein ARBP recognizes a novel DNA sequence motif with high affinity.

Authors:  H Buhrmester; J P von Kries; W H Strätling
Journal:  Biochemistry       Date:  1995-03-28       Impact factor: 3.162

6.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

7.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.

Authors:  R E Amir; I B Van den Veyver; M Wan; C Q Tran; U Francke; H Y Zoghbi
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

8.  Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2.

Authors:  X Nan; R R Meehan; A Bird
Journal:  Nucleic Acids Res       Date:  1993-10-25       Impact factor: 16.971

9.  A matrix/scaffold attachment region binding protein: identification, purification, and mode of binding.

Authors:  J P von Kries; H Buhrmester; W H Strätling
Journal:  Cell       Date:  1991-01-11       Impact factor: 41.582

10.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

View more
  27 in total

1.  Functional consequences of Rett syndrome mutations on human MeCP2.

Authors:  T M Yusufzai; A P Wolffe
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

2.  Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation.

Authors:  M C Lorincz; D Schübeler; M Groudine
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Methylation-dependent silencing at the H19 imprinting control region by MeCP2.

Authors:  Robert A Drewell; Carolyn J Goddard; Jean O Thomas; M Azim Surani
Journal:  Nucleic Acids Res       Date:  2002-03-01       Impact factor: 16.971

Review 4.  Rett syndrome and MeCP2: linking epigenetics and neuronal function.

Authors:  Mona D Shahbazian; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2002-11-19       Impact factor: 11.025

Review 5.  Rett syndrome: clinical review and genetic update.

Authors:  L S Weaving; C J Ellaway; J Gécz; J Christodoulou
Journal:  J Med Genet       Date:  2005-01       Impact factor: 6.318

6.  CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.

Authors:  S M Pulukuri; J S Rao
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

7.  Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin.

Authors:  Tatiana Nikitina; Xi Shi; Rajarshi P Ghosh; Rachel A Horowitz-Scherer; Jeffrey C Hansen; Christopher L Woodcock
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

Review 8.  Evolving role of MeCP2 in Rett syndrome and autism.

Authors:  Janine M LaSalle; Dag H Yasui
Journal:  Epigenomics       Date:  2009-10       Impact factor: 4.778

Review 9.  Recent advances in MeCP2 structure and function.

Authors:  Kristopher C Hite; Valerie H Adams; Jeffrey C Hansen
Journal:  Biochem Cell Biol       Date:  2009-02       Impact factor: 3.626

10.  Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays.

Authors:  Ken Kron; Vaijayanti Pethe; Laurent Briollais; Bekim Sadikovic; Hilmi Ozcelik; Alia Sunderji; Vasundara Venkateswaran; Jehonathan Pinthus; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat
Journal:  PLoS One       Date:  2009-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.